University Of Maryland, Baltimore
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1807-01-01
- Employees
- 7.3K
- Market Cap
- -
- Website
- http://www.umaryland.edu
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
Phase 1
Withdrawn
- Conditions
- Large Cell Neuroendocrine (NE) TumorsSmall Cell Lung Cancer (SCLC)Neuroendocrine (NE) Tumors
- Interventions
- Drug: Rhenium Re 188-P2045
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT02030184
- Locations
- 🇺🇸
University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
Incisional Negative Pressure Dressing on Clean Closed Groin Incisions
Not Applicable
Withdrawn
- Conditions
- Complication of Surgical Procedure
- Interventions
- Other: Standard of Care wound therapyDevice: Incisional Neg Pressure Wound Therapy (Prevena™)
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT02006511
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
Phase 2
Terminated
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Hormonal Therapy with Anastrozole and FulvestrantDrug: Chemotherapy with Eribulin
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 2
- Registration Number
- NCT02000596
- Locations
- 🇺🇸
University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
Lamotrigine Bioequivalence
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 35
- Registration Number
- NCT01995825
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
Borderline Pancreas Study: FOLFIRINOX +SBRT
Early Phase 1
Completed
- Conditions
- Resectable Pancreatic Cancer
- Interventions
- Other: Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicableDrug: -Oxaliplatin 85 mg/m2 IV on Day 1Drug: -Irinotecan 180 mg/m2 IV on Day 1Drug: -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 8
- Registration Number
- NCT01992705
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
Neuroendocrine and Immune Response to Stress in Schizophrenia
Not Applicable
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- Behavioral: Trier Social Stress Test
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 21
- Registration Number
- NCT01975584
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States
Biological Evaluation of Dietary Supplement Liposomal Glutathione
Not Applicable
Completed
- Conditions
- Schizophrenia
- Interventions
- Dietary Supplement: Liposomal glutathioneDietary Supplement: Placebo
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 11
- Registration Number
- NCT01967667
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States
Dissemination of a Theory-Based Bone Health Program in Online
Not Applicable
Completed
- Conditions
- OsteoporosisHealth Behaviors
- Interventions
- Behavioral: TO-BoneHealth Program (Bone Power Program)Behavioral: TO-BoneHealth Plus Program (Bone Power Plus Program)
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 866
- Registration Number
- NCT01963169
A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis
Phase 1
Terminated
- Conditions
- Cirrhosis
- Interventions
- Drug: IV bolus injection of Sildenafil
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 2
- Registration Number
- NCT01954524
- Locations
- 🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States
MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications
Not Applicable
Completed
- Conditions
- Schizophrenia
- Interventions
- Device: SmartphoneBehavioral: MedActive
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 31
- Registration Number
- NCT01953237
- Locations
- 🇺🇸
Outpatient clinics within the University of Maryland Division of Community Psychiatry, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath